Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Hundemer, Gregory L.; Imsirovic, Haris; Vaidya, Anand; Yozamp, Nicholas; Goupil, Rémi; Madore, François; Agharazii, Mohsen; Knoll, Greg; Sood, Manish M.
• Is Part Of: Hypertension. Volume 79:Issue 1(2022)
• Publication Date: 2022-01
• Subjects: aldosterone -- cardiovascular disease -- hypertension -- hypokalemia -- potassium; Hypertension -- Periodicals; Hypertension -- Treatment -- Periodicals; 616.132005
• DOI: 10.1161/HYPERTENSIONAHA.121.18118
• Languages: English
• ISSNs: 0194-911X

Abstract

Abstract : Primary aldosteronism is a common, yet highly underdiagnosed, cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Hypertension plus hypokalemia is a guideline-recommended indication to screen for primary aldosteronism, yet the uptake of this recommendation at the population level remains unknown. We performed a population-based retrospective cohort study of adults ≥18 years old in Ontario, Canada, with hypertension plus hypokalemia (potassium <3.5 mEq/L) from 2009 to 2015 with follow-up through 2017. We measured the proportion of individuals who underwent primary aldosteronism screening via the aldosterone-to-renin ratio based upon hypokalemia frequency and severity along with concurrent antihypertensive medication use. We assessed clinical predictors associated with screening via Cox regression. The cohort included 26 533 adults of which only 422 (1.6%) underwent primary aldosteronism screening. When assessed by number of instances of hypokalemia over a 2-year time window, the proportion of eligible patients who were screened increased only modestly from 1.0% (158/15 983) with one instance to 4.8% (71/1494) with ≥5 instances. Among individuals with severe hypokalemia (potassium <3.0 mEq/L), only 3.9% (58/1422) were screened. Among older adults prescribed ≥4 antihypertensive medications, only 1.0% were screened. Subspecialty care with endocrinology (hazard ratio [HR], 1.52 [95% CI, 1.10–2.09]), nephrology (HR, 1.43 [95% CI, 1.07–1.91]), and cardiology (HR, 1.39 [95% CI, 1.14–1.70]) were associated with an increased likelihood of screening, whereas age (HR, 0.95 [95% CI, 0.94–0.96]) and diabetes (HR, 0.66 [95% CI, 0.50–0.89]) were inversely associated with screening. In conclusion, population-level uptake of guideline recommendations for primary aldosteronism screening is exceedingly low. Increased education and awareness are critical to bridge this gap. Abstract : Supplemental Digital Content is available in the text.